Floatz logo

ONTECIZUMAB

Noncutaneous Extranodal Lymphoma

Morphotekmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Noncutaneous Extranodal Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Case Comprehensive Cancer Center
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Monomethyl Fumarate
University of Medicine and Dentistry of New Jersey
Phase 2BB
Cyclophosphamide
Case Comprehensive Cancer Center
Phase 2B
Busulphan
Case Comprehensive Cancer Center
Phase 2B

View all 36 →

Same molecule, other indications

ONTECIZUMAB is also rated in:

metastatic melanomaDormant
CCC
Indicative ·
54 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →